�����ƽ��

In vitro models and human cell-based assays achieve their highest predictive utility and translational value when standardized through validated models and aligned with evolving regulatory frameworks. Whether scaling complex microphysiological systems (MPS) such as organ-on-chips (OoCs) or building biological datasets for artificial intelligence and machine learning (AI/ML) enabled TechBio workflows, maximizing the impact of modern in vitro models requires a shift toward highly controlled, reproducible platforms. By anchoring these advanced systems with standardized biological reagents, therapy developers can successfully validate a robust test method for its specific Context of Use (CoU), ultimately turning human data into actionable milestones across the drug discovery pipeline. This section will take you through the advanced workflow technologies and regulatory and industry trends shaping the implementation of these modern human cell-based systems.

Technologies Supporting Drug Discovery Workflows

Integrating targeted workflow tools, alongside human cell-based models, offer significant advantages in processing efficiency, throughput capacity, and data standardization. Using specialized cell isolation technologies, automated laboratory instruments, and analytical software can help reduce hands-on time, standardize key steps, and generate cleaner, assay-ready inputs and more efficient downstream applications. For workflows leveraging hematological or specific primary cell populations, solutions like �������⳧���™ for rapid cell isolation and ��Dz��dz����™ for fully automated cell separation provide reproducible pathways to standardize sample preparation. Additionally, high-throughput applications can benefit from specialized sorting tools like �ᾱ����ɲ���1™ or intracellular delivery systems like �������ʴǰ���™ to scale specific assay components across the drug development pipeline.

Learn more about cell isolation technology >

Learn more about laboratory instruments and software >

Building Biological Datasets for AI-Enabled Workflows

As workflows become more standardized, they generate the highly structured, scalable datasets required to support advanced computational modeling. In silico approaches, such as AI/ML, represent a powerful and rapidly evolving class of new approach methodologies (NAMs) in TechBio. While these computational tools excel at extracting patterns from complex data, their predictive utility in the drug discovery pipeline increases exponentially when paired with high-quality, human-relevant experimental inputs.

In this context, standardized primary and stem cell-derived tissue models provide the consistent biological training sets required to build, test, and refine machine learning models. To make this high-dimensional in vitro data more actionable, specialized interpretation platforms are becoming essential; for example, our Visualization Tool for Neural Organoid Single-Cell RNA Sequencing Data illustrates how complex genomic datasets can be mapped and interpreted within automated lead optimization workflows.

Integrating Microphysiological Systems (MPS)

The impact of human in vitro models expands significantly when integrated with advanced microfluidic platforms that introduce physical forces, such as fluid shear stress and multi-tissue communication. MPS, including specialized OoCs, add an essential layer of physiological complexity by more accurately mimicking the dynamic microenvironment of human tissues in vivo.

However, transitioning cells into fluidic environments presents unique biological challenges. Sustaining functional maturation and multi-lineage cellular ratios over extended screening windows requires highly specialized, OoC-compatible, defined media formulations capable of supporting continuous perfusion while maintaining strict tissue-specific barrier integrity.

Explore organ-on-chips resources >

Keep Pace with Drug Discovery Trends

Drug discovery is evolving toward more human-relevant, predictive, and integrated approaches. Across the field, researchers, technology developers, industry groups, and regulatory stakeholders are exploring how NAMs, advanced cell-based models, in silico tools, automation, and data-rich workflows can modernize safety and efficacy assessment.

As these trends continue to develop, global regulatory initiatives focused on best practices and cross-sector alignment are helping define how emerging tools can be evaluated and applied across drug discovery and development. Together, these efforts reflect a growing emphasis on generating high-quality, human-relevant evidence such as non-animal data for Investigational New Drug (IND) filings that can support the discovery and advancement of safer, more effective therapies.